131I-ICF01012 is a quite old product which eventually entered clinical trials in 2018 and targeting the melanin receptors. It is indicated for the diagnostic and treatment of metastasized melanomas. Study completion is expected by November 2022.

Target/Mechanism: melanin

Carrier/Ligand: ICF01012

Radiation Type: beta electrons (β)

< Back